Skip to Main Content

We have a new app!

Take the Access library with you wherever you go—easy access to books, videos, images, podcasts, personalized features, and more.

Download the Access App here: iOS and Android. Learn more here!

INTRODUCTION

Blood must remain fluid within the vasculature and yet clot quickly when exposed to subendothelial surfaces at sites of vascular injury. Under normal circumstances, a delicate balance between coagulation and fibrinolysis prevents both thrombosis and hemorrhage. Alteration of this balance in favor of coagulation results in thrombosis. Thrombi, composed of platelet aggregates, fibrin, and trapped red blood cells, can form in arteries or veins. Antithrombotic drugs used to treat thrombosis include antiplatelet drugs, which inhibit platelet activation or aggregation; anticoagulants, which attenuate fibrin formation; and fibrinolytic agents, which degrade fibrin. All antithrombotic drugs increase the risk of bleeding.

This chapter reviews the agents commonly used for controlling blood fluidity, including:

  • The parenteral anticoagulant heparin and its derivatives, which activate antithrombin, a natural inhibitor of coagulant proteases

  • The coumarin anticoagulants, which lower the functional levels of multiple coagulation factors

  • The direct oral anticoagulants, which inhibit factor Xa or thrombin

  • Fibrinolytic agents, which degrade fibrin

  • Antiplatelet agents, which attenuate platelet activation (aspirin, clopidogrel, prasugrel, ticagrelor, and vorapaxar) or aggregation (glycoprotein IIb/IIIa inhibitors)

  • Vitamin K, which is required for the biosynthesis of key coagulation factors

ABBREVIATIONS

Abbreviations

ACT: activated clotting time

α2-AP: α2-antiplasmin

aPTT: activated partial thromboplastin time

COX: cyclooxygenase

CrCL: creatinine clearance

CYP: cytochrome P450

EPCR: endothelial protein C receptor

Gla: γ-carboxyglutamic acid

Glu: glutamic acid

GP: glycoprotein

INR: international normalized ratio

LMWH: low-molecular-weight heparin

PAI: plasminogen activator inhibitor

PAR: protease-activated receptor

PT: prothrombin time

TF: tissue factor

TFPI: tissue factor pathway inhibitor

t-PA: tissue plasminogen activator

TxA2: thromboxane A2

u-PA: urokinase plasminogen activator

VKOR: vitamin K epoxide reductase

OVERVIEW OF HEMOSTASIS: PLATELET FUNCTION, BLOOD COAGULATION, AND FIBRINOLYSIS

Hemostasis is the cessation of blood loss from a damaged vessel. Platelets first adhere to macromolecules in the subendothelial regions of the injured blood vessel, where they become activated. Adherent platelets release substances that activate nearby platelets, thereby recruiting them to the site of injury. Activated platelets then aggregate to form the primary hemostatic plug.

Vessel wall injury also exposes tissue factor (TF), which initiates the coagulation system. Activated platelets enhance activation of the coagulation system by providing a surface onto which clotting factors assemble and by releasing stored clotting factors. This results in a burst of thrombin (factor IIa) generation. Thrombin converts soluble fibrinogen to fibrin, activates platelets, and feeds back to promote additional thrombin generation. The fibrin strands tie the platelet aggregates together to form a stable clot.

The processes of platelet activation and aggregation and blood coagulation are summarized in Figures 36–1 and 36–2 (see also the animation on the Goodman & Gilman site on AccessMedicine.com). Coagulation involves a series of zymogen activation reactions, as shown in Figure 36–2. At each stage, a precursor protein, or zymogen, is converted to an active ...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.